Gastrointestinal Hemorrhage Clinical Trial
Official title:
Pharmacogenetics of Gastrointestinal Bleeding Under Nonsteroidal Anti-inflammatory Drugs : the Role of Cytochrome P450 2C9
Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because of genetic mutations. We hypothesized that individuals carrying such mutations should be at higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.
Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the
use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for
the elimination of most NSAIDs. Several polymorphisms have been observed in CYP2C9. Of
these, the CYP2C9*3 allele, found in 12% of caucasian subjects, leads to reduced function of
the enzyme.
We hypothesized that individuals carrying this mutation should be at higher risk of
gastrointestinal bleeding since they display decreased elimination of some NSAIDs.
The purpose of this study is to determine whether the frequency for CYP2C9*3 variant allele
is increased in subjects using NSAIDs metabolized by CYP2C9 in comparison with subjects
under NSAIDs not metabolized by this enzyme.
The study groups consist of 200 patients suffering from gastrointestinal bleeding after
NSAIDs use, divided in 100 patients using NSAIDs metabolized by CYP2C9 and 100 patients
using other NSAIDs.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02903017 -
Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage
|
Phase 4 | |
| Recruiting |
NCT02514304 -
Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
|
||
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT01477320 -
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
|
N/A | |
| Completed |
NCT02105532 -
Transfusion in Gastrointestinal Bleeding
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT01549418 -
The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin
|
Phase 4 | |
| Recruiting |
NCT05226221 -
Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
|
||
| Active, not recruiting |
NCT02874326 -
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
|
Phase 2 | |
| Completed |
NCT02928939 -
Therapeutic Conflicts and Multimorbidity
|
||
| Withdrawn |
NCT01215058 -
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer
|
N/A | |
| Completed |
NCT01029626 -
Glasgow-Blatschford Score Validation in Digestive Hemorrhage
|
N/A | |
| Completed |
NCT00251979 -
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
|
Phase 3 | |
| Completed |
NCT02991612 -
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
|
N/A | |
| Recruiting |
NCT02964195 -
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding
|
N/A | |
| Terminated |
NCT02609100 -
Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy
|
N/A | |
| Completed |
NCT02965209 -
European Novel Motorized Spiral Endoscopy Trial
|
N/A | |
| Completed |
NCT02349490 -
Seraseal for Endoscopic Hemostasis
|
Phase 4 | |
| Completed |
NCT01872286 -
Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2
|
N/A | |
| Withdrawn |
NCT01005147 -
Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding
|
N/A | |
| Completed |
NCT00570973 -
Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy
|
Phase 4 |